Curative Effect of DOF Combined with Thalidomide Regimen and DOF Regimen Alone as First-line Treatment for Advanced Gastric Cancer
-
摘要: 目的 观察DOF联合沙利度胺对比单纯DOF方案一线治疗晚期胃癌的疗效及不良反应。方 法 将114例晚期胃癌患者随机分为DOF方案联合沙利度胺组（联合组）和DOF方案组（化疗组），每组均为57例，2周为1个化疗周期。对两组的近期有效率（RR率）、中位疾病进展时间（mTTP）、中位生存时间（MST）、不良反应进行比较分析。结果 联合组和化疗组的有效率分别为61.4%和49.1%（P<0.05）；中位疾病进展时间分别为6.9月和6.0月（P＜0.05）；中位生存时间分别为10.9月和10.5月（P＞0.05）；不良反应：联合组恶心呕吐、腹泻发生率低于化疗组（P<0.05），睡眠改善，但联合组便秘发生率高于化疗组（P<0.05），其余不良反应比较，差异无统计学意义。结论 与单用DOF方案化疗相比，DOF方案联合沙利度胺治疗晚期胃癌有较好的近期有效率及中位疾病进展时间，同时改善患者生活质量，不良反应易于耐受。Abstract: Objective To observe the curative effect and adverse reactions of DOF regimen combined with thalidomide and DOF regimen alone as the first-line treatment for advanced gastric cancer. Methods A total of 114 patients with advanced gastric cancer were randomly divided into DOF combined with thalidomide group(Combination group) and DOF alone group(Chemotherapy group), 57 cases each, two weeks as a cycle. Recent response rate (RR), median time to progression (mTTP), median survival time(MST) and side effects were analyzed after 4 cycles. Results RR of Combination group and Chemotherapy group were 61.4% and 49.1% (P<0.05 ) ; mTTP were 6.9 and 6.0 months (P<0.05); MST were 10.9 and 10.5 months (P> 0.05); the incidence of nausea and vomiting in Combination group were lower than those in Chemotherapy group(P<0.05), but the peripheral neurotoxicity and constipation in Combination group were higher than those in Chemotherapy group(P<0.05); no statistical difference was observed in other side effects. Conclusion Compared with DOF alone, DOF combined with thalidomide in advanced gastric cancer patients has better RR, mTTP and QOL; at the meantime, the side effects are easier to be tolerated.
-
Key words:
- Docetaxel /
- Oxaliplatin /
- 5-Fluorouracil /
- Thalidomide /
- Advanced gastric cancer
-
-
[1] Shigeoka H, Imamoto H, Nishimura Y, et al. Complete response to preoperative chemoradiotherapy in highly advanced gastric adenocarcinoma[J]. World J Gastrointest Oncol, 2010, 2(6): 28 2-6. [2] Armoiry X, Fagnani F, Benboubker L, et al. Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study[J]. J Clin Pharm Ther, 2011, 36(1): 19-26. [3] Liu LQ, Hu SL, Shen G, et al. Clinical observation of PCF and FOLFOX4 in treating intermediate and advanced gastric cancer[J]. Anhui Yi Ke Da Xue Xue Bao, 2013, 48(7): 807-10. [刘 林青, 胡世莲, 沈干, 等. PCF方案和FOLFOX4方案治疗中晚期 胃癌的临床观察[J]. 安徽医科大学学报, 2013, 48(7): 807-10.] [4] Lin Y, Ueda J, Kikuchi S, et al. Comparative epidemiology of gastric cancer between Japan and China[J]. World J Gastroenterol, 20 11, 17(39): 4421-8. [5] Wu JJ, Chen WR. Research Progress of A New-generation Platinum Compounds Oxaliplatin[J]. Yi Xue Zong Shu, 2012, 18 (12): 1906-8.[吴建军, 陈维荣. 新一代铂类药物奥沙利铂的研 究进展[J]. 医学综述, 2012, 18(12): 1906-8.] [6] Ajani JA, Moiseyenko VM, Tjulandin S, et al. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase Ⅲ trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group[J]. J Clin Oncol, 2007, 25(22): 3205-9. [7] Liu HD, Zhu ZY, Yang F. Treatment of advanced gastric cancer with regimen of thaiidomide, oxaliplatin,leucovorin,fluorouracil and hydroxycamptothecin[J]. Zhonghua Zhong Liu Fang Zhi Za Zhi, 2010, 17(21): 1768-70.[刘淮东, 朱子元, 杨飞. 沙利度胺联 合化疗治疗晚期胃癌的临床观察[J]. 中华肿瘤防治杂志, 2010, 17 (21): 1768-70.] [8] Xiang XJ, Zhang L, Qiu F, et al. A phase Ⅱstudy of capecitabine plus oxaliplatin as first-line chemotherapy in elderly patients with advanced gastric cancer[J]. Chemotherapy, 2012, 58(1): 1-7. [9] Sun BX, Zhang JJ, Li QS, et al. Curative effect of Thalidomide on elderly advanced primary liver cancer patients[J]. Zhongguo Lao Nian Xue Za Zhi, 2013, 33(15): 3752-3.[孙宝信, 张晶晶, 李青山, 等. 沙利度胺治疗老年晚期原发性肝癌的疗效[J]. 中国老年学 杂志, 2013, 33(15): 3752-3.]
计量
- 文章访问数: 1616
- HTML全文浏览量: 306
- PDF下载量: 528
下载:
